Platform Partnership Development

About Darwin Biosciences

Darwin Biosciences has developed a breakthrough, self-contained point-of-care diagnostic device that uses saliva to detect the immune signature of acute infections, independent of laboratories or power. Originating from military-funded research, the platform is initially targeting the critical need for early sepsis detection, where timely diagnosis can significantly reduce mortality. The company, which has raised $17 million, is pursuing strategic partnerships to adapt its scalable nucleic acid detection platform for various disease areas, positioning it as a foundational technology for next-generation diagnostics.

Therapeutic Areas

Other Various (Human & Animal Health) Drugs